AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 11 - (NewsRx.com & NewsRx.net) --
by Sonia Nichols, senior medical writer - Using an adenoviral vector expressing genes for the natural angiogenesis inhibitor angiostatin, medical researchers in Canada have prevented the formation of metastatic tumors in murine models of breast cancer.
The new research adds evidence to a growing belief that gene therapies preventing angiogenesis in targeted tissues could be used for treating a number of human diseases. Angiostatin, a protein obtained during plasminogen activity, is just one of a few angiogenesis inhibitors that scientists are investigating for their usefulness in curbing angiogenic processes.
"In this study, we have expressed the cDNA for murine angiostatin under the control of the human cytomegalovirus promoter from a human type-5 adenovirus and shown that this vector produces a protein which retains biological activity," said Steve Gyorffy of the Center for Gene Therapeutics at McMaster University in Ontario, Canada.
Gyorffy's group studied the effects of the vector, called Ad-angiostatin, in cell cultures and in mice implanted with Matrigel plugs containing an angiogenic growth factor or in mice implanted with breast cancer cells.
They reported in the American Journal of Pathology that Ad-angiostatin significantly prevented human umbilical cord vein endothelial cell culture growth, and when administered to mice implanted with plugs containing basic fibroblast growth factor (bFGF), it altered endothelial cell characteristics and prevented ...